The IN VIVO Blog (blog) | Deals Of The Week: Isis Rethinks Its Partnering Strategy The IN VIVO Blog (blog) ... arthritis drug Humira (adalimumab). The collaboration will involve biosimilar versions of four oncology drugs, including Roche/Genentech Inc.'s Rituxan (rituximab), Bristol-Myers Squibb Co./Eli Lilly & Co.'s Erbitux (cetuximab), Roche/Genentech's ... |
